My SciELO
Custom servicesServices on Demand
Journal
Article
Spanish (pdf)
Article in xml format
Article references
Automatic translation
Send this article by e-mailIndicators
Cited by SciELO 
Access statistics
Related links
Cited by Google 
Similars in
SciELO 
Similars in Google
Share
Permalink
Nefrología (Madrid)
On-line version ISSN 1989-2284Print version ISSN 0211-6995
Abstract
DE’MARZIANI, G. et al. Glycaemic changes in patients with chronic kidney disease. Nefrología (Madr.) [online]. 2016, vol.36, n.2, pp.133-140. ISSN 1989-2284. https://dx.doi.org/10.1016/j.nefro.2015.10.011.
In Argentina, there have been no studies aimed at establishing the prevalence of dysglycaemia (impaired fasting glucose [IFG], impaired glucose tolerance [IGT] and diabetes mellitus [DM]) in patients with chronic kidney disease (CKD). Our group decided to conduct an observational study to evaluate the frequency with oral glucose tolerance test (OGTT) in CKD patients with no previous data for dysglycaemia in their medical records.
OGTT was performed in 254 patients (60.62% male) with stage 3, 4 and 5 CKD under conservative treatment, haemodialysis or transplantation.
Results for DM were found in 10 patients according to fasting glucose alone (3.94%; 95% CI: 1.35-6.53%), 11 patients with exclusively the second hour criterion (4.33%; 95% CI: 1.63-7.03%), 15 with both criteria (5.91%; 95% CI: 2.81-9.00%) and 36 patients with at least one criteria (14.17%; 95% CI: 9.69-18.66%). In a multivariate analysis, DM was associated with waist circumference (OR = 1.033 per cm; 95% CI, 1.005 to 1.062; P = .019) and with conservative treatment vs. replacement therapy (OR = 0.41; 95% CI: 0.19-0.92; P = .028). IGT was evident in 24.6% and 20.3 on conservative vs. replacement therapy, with no statistically significant difference. IFG (ADA criteria) was 19.75 vs. 9.24% in conservative vs. replacement therapy, with a statistically significant difference.
OGTT is suggested for all CKD patients since it is able to detect the full range of unknown dysglycaemias, which avoids underdiagnoses and favours performing treatments to prevent progression in DM risk groups (IFG and/or IGT). It also aids in the selection of the most appropriate medication for transplantation or treatment initiation in new cases of undiagnosed DM to decrease morbidity and mortality.
Keywords : Oral glucose tolerance test; Chronic kidney disease; Diabetes; Impaired fasting glucose; Impaired glucose tolerance; Haemodialysis; Transplantation.
